國家衛生研究院 NHRI:Item 3990099045/2970

NHRI > National Institute of Cancer Research > Jacqueline Whang-Peng(1996-2007) > Periodical Articles > Item 3990099045/2970

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2970

Title:	Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
Authors:	Yang, CH;Chen, MC;Cheng, AL;Hsu, CH;Yeh, KH;Yu, YC;Whang-Peng, J;Yang, PC
Contributors:	National Institute of Cancer Research
Abstract:	Objective: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. Methods: Eligibility criteria included inoperable stage IIIB or IV NSCLC patients, Eastern Cooperative Oncology Group performance status of 0-2, measurable or evaluable disease and adequate organ function. Epirubicin 70 mg/m(2) intravenous infusion for 15 min was given on day 1. Paclitaxel 175 mg/m(2) intravenous infusion for 3 h was given on day 2. Cycles were repeated every 21 days. Tumor response was evaluated every two cycles. Patients received treatment until disease progression, unacceptable toxicity or stable disease after cycle 6. Results:Thirty-eight patients received a total of 185 cycles (median 6 cycles). Seventeen patients responded to treatment (response rate 44.7%). Twenty-six (68%) patients received second-line chemotherapy. All patients were followed until their death. Median survival was 11.9 months (95% confidence interval 9.0-14.9 months). Median time-to-treatment-failure was 4.6 months. Conclusion: Conventional dose epirubicin plus paclitaxel is effective as a first-line treatment for inoperable NSCLC patients.
Keywords:	Oncology
Date:	2005
Relation:	Oncology. 2005;68(4-6):350-355.
Link to:	http://dx.doi.org/10.1159/000086974
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0030-2414&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000231468900008
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=23844505957
Appears in Collections:	[Jacqueline Whang-Peng(1996-2007)] Periodical Articles

Files in This Item:

File	Description	Size	Format
000231468900008.pdf		115Kb	Adobe PDF	343	View/Open

Loading...